Modeling meropenem treatment, alone and in combination with daptomycin, for KPC-producing Klebsiella pneumoniae strains with unusually low carbapenem MICs

P. Gagetti, F. Pasteran, M. P. Martinez, M. Fatouraei, J. Gu, R. Fernandez, L. Paz, W. E. Rose, A. Corso, A. E. Rosato

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Klebsiella pneumoniae strains producing K. pneumoniae carbapenemase (KPC) cause serious infections in debilitated and immunocompromised patients and are associated with prolonged hospital stays and increased mortality rates. Daptomycin is a lipopeptide used against Staphylococcus aureus infection and considered inactive against Gram-negative bacteria. We investigated the effectiveness of a daptomycin-meropenem combination by synergy kill curve and a pharmacokinetic/pharmacodynamic model. The combination may represent a novel therapeutic strategy against infections caused by KPC-producing K. pneumoniae strains.

Original languageEnglish (US)
Pages (from-to)5047-5050
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Volume60
Issue number8
DOIs
StatePublished - Aug 2016

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Modeling meropenem treatment, alone and in combination with daptomycin, for KPC-producing Klebsiella pneumoniae strains with unusually low carbapenem MICs'. Together they form a unique fingerprint.

Cite this